# **Special Issue**

# Translational Research and Novel Therapeutics in Cutaneous Melanoma

## Message from the Guest Editors

There has been an alarming increase in the global incidence of melanoma. Previous research in the immunology and pathophysiology of melanoma has led to groundbreaking discoveries, facilitating the development of innovative and personalized treatment modalities. These advancements are contributing to a reduction in mortality rates and an improvement in the quality of life for patients diagnosed with malignant melanoma. Despite these significant discoveries, there remains a critical need for a deeper understanding of tumor pathology to develop novel therapeutic agents.

This Special Issue aims to present the most recent advances in the field of translational research and novel therapeutics in cutaneous melanoma and their implications for the future care of melanoma patients. We invite colleagues worldwide to submit their research in this area in the form of original articles and state-of-the-art reviews. Submissions may include topics such as the immunopathology of melanoma, novel biomarkers, cell therapies, tumor vaccines, and emerging technologies for the early diagnosis of cutaneous melanoma (Al and digital dermoscopy) to be considered for inclusion in this Special Issue.

### **Guest Editors**

Dr. Maja Tolušić Levak

- 1. Department of Dermatovenereology, University Hospital Osijek, Osijek, Croatia
- 2. Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia

## Prof. Dr. Martina Mihalj

- 1. Department of Dermatovenereology, University Hospital Osijek, Osijek, Croatia
- 2. Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia

# Deadline for manuscript submissions

31 January 2026



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/213493

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



# About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

### Editor-in-Chief

### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

### **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

